AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04776447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) plating. Stability: 24 hours at ambient temperature in 5% glucose, glucosamine or physiologic saline. It is recommended not to dilute with chlorinated solutions for this could affect the carboplatin.~Route of administration: Intravenous infusion.~Guidelines of Carboplatin administration: According to the standard of each center.~Other Name: ATC code: L01XA02
Study NCT04776447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placlitaxel
Description: Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexahidroxytax-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more than 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines of Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml.
Study NCT04776447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is a humanized immunoglobulin (IgG1) monoclonal antibody that is produced in Chinese hamster ovary (CHO) cells. Atezolizumab targets programmed death-ligand 1 (PD-L1) on tumor-infiltrating immune cells (ICs) or tumor cells (TCs) and prevents interaction with the programmed death-1 (PD-1) receptor and B7.1 (CD80), both of which function as inhibitory receptors expressed on T cells and other immune cells.~Patients will receive 1200 mg of atezolizumab administered by IV infusion every 21 days (+/- 3 days) in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions.
Study NCT06350240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: An exercise program that can be easily applied at home and in the park, which will support the psychomotor, tactile and proprioceptive-rich sensory development specific to children with joint hypermobility. The family will be instructed to do these exercises for 30 minutes a day for 5 days in total, 2 days a week in the playground and 3 days at home for 6 weeks, and the family will be asked to keep a diary to see whether they do the exercises or not.
Study NCT06350240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise+texture insoles
Description: In addition to exercise, children in this group will have an individual textured insoles made to suit the child's foot. The child will be asked to place textured insoles inside his shoes and use the textured insoles for 6-8 hours.
Study NCT04842682 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Combi 3 group
Description: CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 3.0 and 1.0 mg/injection, i.e. 1.2 ml subcutaneous route in right deltoid; and combined with DNA at 4.0 mg/injection, i.e. 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1.2 ml subcutaneous route in right deltoid and 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24.
Study NCT04842682 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Late boost CD40 alone
Description: CD40.HIVRI.Env at 0.3 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at week LB (late boost)
Study NCT04842682 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Late boost CD40 adjuvanted
Description: CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 0.3 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at week LB (late boost)
Study NCT06578455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) Powder
Description: 66.68 mg CBD per capsule for a total of 400 mg CBD per serving
Study NCT06578455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol 100 MG/ML [Epidiolex]
Description: 100 mg CBD/mL for a total of 400 mg CBD per serving
Study NCT05088694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peaceful Coexistence
Description: The Peaceful Coexistence intervention seeks to target important risk and protective factors related to tolerance and acceptance.~The Anti-Extremism intervention seeks to take the same risk and protective factors covered in the Peaceful Coexistence intervention and have students' psychosocial factors shift their skills and behavior.
Study NCT05389332 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hispanics Skin Cancer intervention
Description: With the insights from the community, the investigators will then develop the mobile intervention targeting Hispanics at risk for skin cancer to promote sun protection and SSE and get feedback to optimize the intervention. After the random allocation participants will receive instructions on how to use WhatsApp and then the intervention. They will receive WhatsApp messages about skin cancer for three months with optimal frequencies determined by prior aims and complete a post-intervention survey which contains the same questions in the pre-survey. The pilot RCT will be conducted around the spring/summer of Year four of the R00 when UVR is generally the highest in the US. The participants will be contacted at six months after the baseline survey to complete another survey similar to the post-intervention survey.
Study NCT05389332 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group: physical activity and nutrition for Hispanics
Description: Content will be developed from established websites such as CDC's Division of Nutrition, Physical Activity and Obesity. We selected these topics because they are also of concern among Hispanics and provide an unrelated attention control.
Study NCT06358872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin for Oral Suspension
Description: Azithromycin will be administered as a single dose, in oral suspension form for children. The dose will be calculated by age or height depending on the child's age Both dosing cups and syringes will be used to administer treatment. For children too young to drink out of a dosing cup, a 1 ml or 5 ml syringe will be used, and the calculated dose will be rounded upwards to the nearest 0.2 ml.
Study NCT04633252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: For mCSPC patients, prednisone is optional and if given, should be taken orally, at 5 mg once a day. For mCRPC patients, prednisone should be taken orally either, at 5mg twice a day for each dose or 10 mg once a day as is the patient s preference.
Study NCT04633252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: M7824 (2400 mg) will be administered as a 1 hour intravenous (IV) infusion once every three weeks.
Study NCT04633252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m\^2 will be administered intravenously every 21 days (i.e., a 3-week cycle) for up to 6 cycles in mCSPC and until progression or unacceptable toxicity in mCRPC.
Study NCT05124678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid Tablets
Description: High dose of isoniazid
Study NCT06469268 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epro software
Description: EPRO software：patients with symptoms will fill in report forms via the software, when the data upload to the terminal, the doctor according to the results of the upload ePRO corresponding medical assessment,and give advises.
Study NCT05523739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI-1558
Description: An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).
Study NCT05406895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% Lidocaine with 1:100,000 epinephrine
Description: 2% Lidocaine with 1:100,000 epinephrine will be used for administering the lower jaw anesthesia (inferior alveolar nerve block).
Study NCT05406895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Lidocaine with 1:100,000 epinephrine
Description: 2% Lidocaine with 1:100,000 epinephrine will be used for administering the lower jaw anesthesia (inferior alveolar nerve block).
Study NCT04914663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Exercise training performed at home under remote live supervision over 12 weeks while patients undergo chemotherapy for breast cancer.
Study NCT04914663 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Exercise training performed at home under remote live supervision over 12 weeks while patients undergo chemotherapy for breast cancer.
Study NCT04837040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paltusotine
Description: Paltusotine, tablets, once daily by mouth
Study NCT04837040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, tablets, once daily by mouth
Study NCT05098288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicentre Pain Monitor + Unified Protocol
Description: The intervention will consist in a self-applied online transdiagnostic intervention for emotional problems together with an app-based EMA. In terms of monitoring, the Multicentre Pain Monitor is a mobile app whose contents have been adapted to conduct ecological momentary assessments in different health conditions. The app assesses important psychological variables, namely anxiety, depressive symptoms,etc. Participants respond daily to the questions in the app. In terms of the online self-applied intervention, the Unified Protocol is a transdiagnostic extension of CBT which works on regulate emotions in a more adaptive way through 5 core treatment modules: present-focused emotional awareness, cognitive flexibility, identification and prevention of emotional avoidance patterns, increasing awareness and tolerance to emotion-elicited physical sensations, and graded (interoceptive and situational) exposure procedures.
Study NCT04956484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab 10 mg/kg
Study NCT04956484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Steroid(≤1mg/kg/d) with or without proper immunosuppressants：CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.
Study NCT05637450 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blue Whiting Protein Hydrolysate
Description: 25g Blue Whiting Protein Hydrolysates mixed with an everyday food / drink product daily for 6 weeks
Study NCT05637450 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isocalorific maltodextrin citrus flavoured powder mixed with an everyday food / drink product for 6 weeks
Study NCT06337409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic empagliflozin 25 mg film-coated tablets
Description: Empagliflozin 25 mg film-coated tablets
Study NCT05346302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pneumovax 23
Description: At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.
Study NCT05346302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Typhim VI
Description: At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.
Study NCT05346302 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.
Study NCT04633252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M9241
Description: M9241 at escalating doses and then at RP2D will be administered as a subcutaneous injection every three weeks.
Study NCT04948619 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Vaccine
Description: Patients will have lab evaluations for immune function at baseline, 3, 6, 9 and 24 months post completion of treatment. At 3 months off therapy, patients with abnormal vaccine antibody titers will be randomized to receive either single booster vaccines or to begin a full revaccination series that models post-hematopoietic stem cell transplant vaccination strategies.
Study NCT05856838 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovaSure ablation
Description: Ablation of the endometrial tissue using the NovaSure device
Study NCT06447207 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy Led Social Prescription
Description: The intervention includes encouragement to participate in the co-designed social prescription with 6 monthly sessions with an occupational therapist or occupational therapy doctoral student.
Study NCT05086796 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Substance Use Treatment and Recovery Team (START)
Description: START is a model of care based on Collaborative Care. START is team driven, population-focused, measurement based, and focused on promoting adoption of evidence-based interventions. The purpose of this model is to increase adoption of evidence-based interventions for opioid use disorder and to increase linkage to aftercare.~The components of the START intervention are as follows:~1. Triage~2. Engage, Assess, and Plan~3. Treat~4. Communicate and Coordinate~5. Follow up~6. Monitor
Study NCT05307692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant
Description: Seltorexant 20 mg will be administered orally as a tablet.
Study NCT05307692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered orally as a tablet.
Study NCT05206773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venglustat (GZ402671)
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study NCT05206773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study NCT05076513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: In Phase 0, 300mg administered orally QD for 4 days prior to resection.~In the Expansion cohort/Maintenance phase, niraparib will be administered as described below:~* For patients weighing \<77 kg (\<170 lbs) OR with a platelet count \<150,000/mcL, the recommended dosage is 200 mg taken orally once daily.~* For patients weighing ≥77 kg (≥170 lbs) AND a platelet count ≥150,000/ mcL, the recommended dosage is 300 mg taken orally once daily.
Study NCT06337409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Generic empagliflozin 25 mg film-coated tablets
Description: Empagliflozin 25 mg film-coated tablets
Study NCT02215629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-4718
Study NCT05529953 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oleanolic acid (CAS no. 598-02-1; PubChem CID 10494)
Description: Postprandial study of bioavailability of Oleanolic acid, formulated as functional olive oil, in healthy subjects
Study NCT05529953 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control commercial olive oil
Description: Postprandial study of Oleanolic acid bioavailability in healthy subjects
Study NCT05737498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: Transcranial direct current stimulation will use to deliver a constant direct current through two surface electrodes, Anodal stimulation was applied according to the 10-20 international system for EEG electrode placement, over F3 of the dorsolateral prefrontal cortex (DLPFC), while the cathode was placed over the contralateral supraorbital area for 20 min, on alternate days for 2 weeks 6 sessions with working memory training task. the anode (positive) and the cathode (negative). To reduce resistance and minimize discomfort during application (the electrodes were covered in 35 cm2, saline-soaked sponges
Study NCT04795362 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood sample
Description: 5 tubes of 1 milliliters (ml) will be sampled on a catheter placed as part of the usual practice every hour for 4 hours (at Time 0, at Time 1 hour, at time 2hours, at Time 3 hours, at time 4 hours) as soon as DCI is suspected.~In the event of a mechanical angioplasty decision, the samples will be continued (Time 0, Time 2 hours, Time 4 hours, Time 6hours, Time 12 hours, Time 24 hours, so 6 samples of 1 ml).
Study NCT06357702 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Self Regulation Telehealth
Description: 2 sessions of an intervention delivered via telehealth. Session 1 includes awareness and strategies for monitoring habits and 4 exercises to practice 5 times per day. Session 2 will be 2 weeks later and is a review of session 1 and an introduction to diaphragmatic breathing. Breathing is practiced for 15 minutes twice per day.
Study NCT06357702 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-education Telehealth
Description: 2 sessions of an intervention delivered via telehealth. Session 1 includes discussing trigeminal nerve function, jaw and muscle anatomy, posture, pain referral patterns, and stress biology. Participants rate pain and jaw fatigue 5 times per day. Session 2 will be 2 weeks later and consists of checking on the homework and information from session 1,followed by a discussion of autonomic nervous system activity, and a discussion of sleep quality and sleep hygiene. Participants will be instructed to rate their stress levels, pain, and mood several times per day, similar to the times when participants in the PSR-TH condition would be practicing diaphragmatic breathing
Study NCT05474677 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: closure of the abdominal fascia
Description: The abdomen will be closed in intervention group with continuous PDS 2\\0 sutures and size zero in control group.
Study NCT05664945 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pulmonary tele-rehabilitation (PTR)
Description: PTR is delivered from promoter hospital to a group of 4-6 patients who exercise at home and communicate via tablet-camera.~Each session is 60 min; 35 min exercise/ 25 min patient education, two times per week for a duration of 10-weeks (primary endpoint).~Specific exercises are evidence-based; been used in several intervention studies on patients with COPD.~Exercises involves larger muscle groups with 50/50 exercises for upper and lower extremities. Volume, intensity and content exercise protocol follow both national and international exercise recommendations.~The education sessions consist of dialogue, reflections around empowerment and better living with COPD.~Every fourth education session consists of 25 min Mindfulness exercises developed for COPD patients.~After 10-weeks of PTR, participants are offered once weekly PTR for 60min in groups of 4-8 persons throughout a 65-week maintenance period (secondary endpoint 75-weeks from baseline).
Study NCT05664945 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home-based pulmonary rehabilitation (HPR)
Description: HPR is an individual self-initiated home-based PR aiming to achieve 20 min of self-initiated muscle-endurance based exercise; 3-days/weekly for 10-weeks (primary endpoint).~Exercises are evidence-based; used in several intervention studies on patients with COPD and involves larger muscle groups with 50/50 exercises for upper/lower extremities.~First session is a home visit by a respiratory physiotherapist. During the visit the physiotherapist and patient establish exercise goals, exercise prescription and provision of mindfulness exercises and educationbook.~The home visit is followed by one weekly session for 10-weeks. A menu of topics relevant to COPD and self-management is discussed. A session is delivered from promoter hospital via tablet-camera or telephone call (patients' preference).~After 10-weeks of HPR, participants are offered once weekly PTR for 60min in groups of 4-8 persons throughout a 65-week maintenance period (secondary endpoint 75-weeks from baseline).
Study NCT05664945 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Receive usual care; medication, scheduled follow-up visit and possible phone contact with GP and the outpatient respiratory department.~Except for assessment visits 10-, 35-, and 75-weeks from baseline no intervention is offered.~If a patient changes his/her mind and wishes to participate in a conventional hospital- or community-based PR program, it will be granted as this is a highly recommended treatment (e.g. rehabilitation after hospital admitted exacerbation).
Study NCT06190119 — intervention group
Intervention type: OTHER
Intervention: none intervention
Description: This study has no intervention
Study NCT05349123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Breathing
Description: Subject will be expected to do 12 weeks of home-based rehabilitation, 6 days a week in their home. The proposed project explores the addition of a mindful breathing module, which involves daily guided breathing practice with feedback to encourage mindful breathing.
Study NCT05349123 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-Based Pulmonary Rehabilitation
Description: Subject will be asked to complete exercise guided by a video six days a week and to complete mindful walking six days per week. They will receive weekly health coaching calls.
Study NCT05349123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-Based Pulmonary Rehabilitation
Description: Subject will be asked to complete exercise guided by a video six days a week and to complete mindful walking six days per week. They will receive weekly health coaching calls.